Pyrazolo [1, 5-a] pyridine derivative as well as preparation method and application thereof

By developing pyrazolo[1,5-a]pyridine derivatives, the problems of the effectiveness and safety of existing RET kinase inhibitors have been solved, and effective inhibition of RET abnormal tumor cells has been achieved, providing a high Drugs for selective treatment of abnormal RET diseases.

CN118978537APending Publication Date: 2024-11-19SHANGHAI DAIDAI INVESTMENT CONSULTING CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411046196.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-03-02
Filing Date
2020-03-02
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing RET kinase inhibitors have problems with efficacy, safety and selectivity, resulting in poor effectiveness in the treatment of RET abnormal tumors and lack of highly selective small molecule kinase inhibitors for RET proteins.

Method used

A pyrazolo[1,5-a]pyridine derivative was developed, which can effectively inhibit the activity of RET kinase through specific chemical structure design, and is used to prepare RET or mutation RET inhibitors for the treatment of RET abnormalities. Mediated diseases such as non-small cell lung cancer, thyroid cancer, etc.

Benefits of technology

The compound showed significant inhibitory effects of tumor cell proliferation and RET enzyme activity inhibition, providing a potential highly selective drug selection for the treatment of RET abnormal diseases, improving the effectiveness and safety of existing RET kinase inhibitors .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978537A_ABST
    Figure CN118978537A_ABST
Patent Text Reader

Abstract

The invention relates to a pyrazolo [1, 5-a] pyridine derivative, a preparation method thereof and application of the pyrazolo [1, 5-a] pyridine derivative in medicine. Specifically, the invention relates to a pyrazolo [1, 5-a] pyridine derivative as shown in a general formula (I), a preparation method and a medicinal salt thereof, and application of the pyrazolo [1, 5-a] pyridine derivative and the medicinal salt thereof as a therapeutic agent, especially an RET inhibitor, and definition of each substituent in the general formula (I) is the same as that in the specification. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of PCT international application number: PCT / CN2020 / 077449, PCT international application date: 2020-03-02, application name: Pyrazolo[1,5-a]pyridine derivatives, preparation methods and uses thereof; the national application number entering the Chinese national phase is: 2020800175866, application name: Pyrazolo[1,5-a]pyridine derivatives, preparation methods and uses thereof, and the application date is: 2020-03-02. Technical Field

[0002] The present invention belongs to the field of medicine and relates to a pyrazolo[1,5-a]pyridine derivative, a preparation method thereof, a pharmaceutical composition containing the derivative and the use of the derivative as a therapeutic agent, in particular as a RET protein kinase inhibitor. Background Art

[0003] RET protein (Rerranged during Transfection) belongs to the receptor tyrosine kinase family. As a receptor for nerve growth factor, its function involves the normal growth and development of the nervous system, cell proliferation and survival. Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFL) regulate downstream signals by binding to RET. The GFL family also includes neurturin (NTRN), artemin (ARTN) and persephin (PSPN) (Arighi et al., Cytokine Growth Factor rev., 2005, 16, 441-67). Unlike other receptor tyrosine kinases, RET activation requires ligands. GDNF family receptor α protein and RET protein form a multimeric complex. GFRα receptors are connected to co-receptors on the cell surface through glycosylphosphatidylinositol bonds. It has been found that this family includes 4 subtypes (GFRα1-4) that can bind to different GFLs. First, GFL and GFRα family members form a binary complex, which then binds to RET and recruits it to the cholesterol-rich secondary domain on the cell membrane called lipid rafts, inducing RET to dimerize and form a GFL(2)-GFRa(2)-RET(2) heterohexameric complex, activating RET kinase activity and downstream signaling.

[0004] After binding to the ligand-co-receptor complex, RET dimerizes and induces autophosphorylation of intracellular tyrosine residues of the protein, and then further recruits other connecting proteins and signaling proteins to activate multiple mid- and downstream signaling pathways, including the Ras-MAPK pathway and the PI3K-Akt / mTOR signaling pathway.

[0005] RET abnormalities are closely related to the occurrence and development of tumor diseases, mainly manifested as gain-of-function gene mutations or RET fusion proteins produced by gene rearrangement, both of which can cause persistent abnormal activation of RET signals. For example, in patients with familial medullary thyroid cancer, the proportion of RET point mutations is as high as 95%; in patients with papillary thyroid cancer, the incidence of RET gene rearrangement is about 20% to 40%; in addition, overexpression of RET protein can also be observed in breast cancer, colon cancer, pancreatic cancer, and acute leukemia. (Lois M.Mulligan; RET revisited expanding the oncogenic portfolio, Nature Reviews Cancer 14, 173-186 (2014)). The above-mentioned tumors with RET fusion proteins and RET point mutations all rely on RET kinase activation to maintain the proliferation and survival of tumor cells. This dependence is usually called "oncogene addiction", which makes these tumors highly sensitive to small molecule kinase inhibitors targeting RET. At present, some small molecule kinase inhibitors targeting multiple kinases have inhibitory activity against RET kinases, such as Vandetinib and Cabozantinib, which have been approved by the FDA for the treatment of thyroid cancer. Others such as Ponatinib, Nintedanib, and Lenvatinib are also conducting clinical studies on tumors with abnormal RET signal activation. However, due to the lack of selectivity for RET protein, the above-mentioned multiple kinase inhibitors have different problems in efficacy and safety, which limits their further research and application in RET abnormal tumors. Therefore, small molecule kinase inhibitory compounds with high selectivity targeting RET protein are urgently needed in clinical practice.

[0006] A series of patents for selective RET kinase inhibitors have been disclosed, including WO2017011776, WO2018071447, WO2018136661, etc. The drug in Phase II clinical research is mainly LOXO-292. However, the compounds disclosed in these prior arts and experimental drugs still have problems in terms of effectiveness, safety or selectivity. In addition, the current understanding of the role of RET in tumors is also deepening. It is still necessary to research and develop new small molecule selective RET kinase inhibitors to fill and meet the clinical treatment needs for RET abnormal diseases. Summary of the invention

[0007] The present inventors unexpectedly discovered through experimental studies that the compound of the following formula (I) can effectively inhibit RET kinase,

[0008]

[0009] in:

[0010] Ring A is selected from the group:

[0011]

[0012] X 1 , X 2 Each independently selected from CH, CCH3, CF, CCl or N;

[0013] X 3 , X 4 are each independently selected from CH, CF or N;

[0014] Where X 1 , X 2 , X 3 and X 4 0, 1 or 2 of them are N;

[0015] L1 is selected from a bond, -(R a R b C)-、-(R a R b N)-or-O-;

[0016] L2 is selected from a bond, -(alkylene)-, -C(O)-, -S(O)-, -SO2-, -(alkylene)-O-, -(alkylene)-S-, -(alkylene)-NR 1 -, -C(O)-(alkylene)-, -SO2-(alkylene)-; wherein the right key of the L2 group is connected to E; wherein the alkylene group is optionally further substituted with one or more selected from hydroxyl, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 2 R3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 substituted by a substituent;

[0017] R a is selected from a hydrogen atom, an alkyl group or a halogen;

[0018] R b is selected from a hydrogen atom, an alkyl group or a halogen;

[0019] Or, R a and R b Together with the C or N atom to which it is connected, it forms a 3-6-membered cycloalkyl or heterocyclic group, wherein the heterocyclic group contains one or more N, O, S(O) n Atoms, wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 substituted by a substituent;

[0020] B is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from R c substituted by a substituent;

[0021] E is selected from hydrogen, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl; wherein the cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R3 or -SO2NR 2 R 3 substituted by a substituent; preferably phenyl or pyridyl;

[0022] R c is selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -S(O)2NR 2 R 3 wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R 6 or -SO2NR 5 R 6 substituted by a substituent;

[0023] R 1 are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group, an alkyl group, a halogen group or an alkoxy group, wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group or an alkoxy group;

[0024] R 2 , R 3 and R 4 Each is independently selected from a hydrogen atom, a hydroxyl group, a halogen, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, a halogen, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R6 or -SO2NR 5 R 6 substituted by a substituent;

[0025] Or, R 2 and R 3 Together with the connected N atom, it forms a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic ring contains one or more N, O, S(O) n atom, and the 4- to 8-membered heterocyclic ring is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R 6 or -SO2NR 5 R 6 substituted by a substituent;

[0026] R 5 , R 6 and R 7 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;

[0027] m is selected from 0, 1, 2, 3, 4 or 5;

[0028] n is selected from 0, 1 or 2;

[0029] Provided that, when ring A is selected from the group:

[0030] hour,

[0031] (1) L1 is selected from -(R a R b C)-,-(R a R b N)-or-S-;

[0032] (2) When L1 is selected from one group, B is selected from alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more selected from R c substituted by a substituent.

[0033] A preferred embodiment of the present invention is a compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, which is a compound represented by general formula (II) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof:

[0034]

[0035] in:

[0036] L1 is selected from a bond, -(R a R b C)-、-(R a R b N)- or -O-; preferably -O-;

[0037] L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 , R a , R b and m are as defined in the general formula (I).

[0038] A preferred embodiment of the present invention is a compound represented by general formula (I) or its stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, which is a compound represented by general formula (III) or its stereoisomer, tautomer or a pharmaceutically acceptable salt thereof:

[0039]

[0040] in:

[0041] (1) L1 is selected from -(R a R b C)-、-(R a N)-or-S-;

[0042] Preferably, R a and R b is selected from a hydrogen atom or a methyl group;

[0043] (2) When L1 is selected from a bond, B is selected from alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more selected from R c substituted by a substituent;

[0044] L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 , R a , R b , R c and m are as defined in the general formula (I).

[0045] A preferred embodiment of the present invention is a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, wherein:

[0046] X 1 , X 2 , X 3 , X 4 is selected from CH or N;

[0047] X 1 , X 2 , X 3 and X 4 0, 1 or 2 of them are N;

[0048] Preferably, X 1 N, X 2 , X 3 , X 4 For CH.

[0049] A preferred embodiment of the present invention is a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, wherein:

[0050] L2 is selected from a bond, -(alkylene)-, -C(O)-, -SO2-, -(alkylene)-O-, -(alkylene)-S-, -(alkylene)-NR 1 - or -C(O)-(alkylene)-, wherein the right bond of the L2 group is connected to E;

[0051] Preferably -(alkylene)-, -C(O)-, -(alkylene)-S- or -C(O)-(alkylene)-;

[0052] The -(alkylene)- is preferably -(methylene)- or -CH(CH3)-.

[0053] A preferred embodiment of the present invention is a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, wherein B is selected from:

[0054] (i) a 5- to 6-membered heteroaryl group, wherein the heteroaryl group is optionally further substituted by one or more substituents selected from alkyl or halogen;

[0055] Preferably, B is selected from pyrazolyl, wherein the pyrazolyl is optionally further substituted with methyl;

[0056] (ii) an alkyl group, wherein the alkyl group is optionally further substituted with one or more hydroxyl groups; preferably,

[0057] B is selected from the group:

[0058] (iii) alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more hydroxyl groups;

[0059] Preferably, when L1 is a bond, B is selected from the group consisting of:

[0060]

[0061] Typical compounds of the present invention include, but are not limited to:

[0062]

[0063]

[0064] The above-mentioned typical compounds include stereoisomers, tautomers or pharmaceutically acceptable salts thereof.

[0065] Furthermore, the present invention provides a method for preparing a compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, the method comprising:

[0066]

[0067] Reacting the general formula (IA) with E-(alkylene)-OMs, EC(O)X, E-(alkylene)-C(O)X or EC(O)H to obtain the general formula (I);

[0068] X is selected from hydroxyl or halogen, preferably hydroxyl, Cl or Br;

[0069] Among them: L1, L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in the general formula (I).

[0070] The present invention provides a compound of general formula (IA) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof.

[0071]

[0072] Where: L1, B, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in the general formula (I).

[0073] Typical compounds of formula (IA) include, but are not limited to:

[0074]

[0075]

[0076] The above typical compounds include stereoisomers, tautomers, free forms or other pharmaceutically acceptable salts thereof.

[0077] Furthermore, the present invention provides a pharmaceutical composition, which contains an effective dose of a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

[0078] The present invention provides a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, and use of their pharmaceutical compositions in the preparation of drugs for RET or mutant RET inhibitors.

[0079] The present invention provides a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, and their pharmaceutical compositions for use in preparing drugs for treating diseases mediated by RET abnormalities, wherein the diseases are preferably cancer, fibrous dysplasia and genetic disorders, wherein the cancer is preferably non-small cell lung cancer, thyroid cancer, solid tumors, colon tumors or pancreatic cancer, and more preferably non-small cell lung cancer, thyroid cancer, solid tumors.

[0080] The present invention provides a compound represented by general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, and use of their pharmaceutical compositions in preparing drugs for treating subjects who produce antibodies to cancer.

[0081] Detailed description of the invention

[0082] Unless otherwise stated, some of the terms used in the specification and claims of the present invention are defined as follows:

[0083] "Alkyl" refers to a saturated aliphatic hydrocarbon group, comprising 1-20 carbon atoms, or 1-10 carbon atoms, or 1-6 carbon atoms, or 1-4 carbon atoms, or 1-3 carbon atoms, or 1-2 carbon atoms, a saturated straight chain or branched monovalent hydrocarbon group, wherein the alkyl group may be independently optionally substituted with one or more substituents described herein. Further examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group may be optionally substituted or unsubstituted.

[0084] "Alkenyl" refers to a linear or branched monovalent hydrocarbon group of 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, wherein at least one CC is sp 2 Double bond, wherein the alkenyl group can be independently optionally substituted by one or more substituents described in the present invention, wherein specific examples include, but are not limited to, vinyl, allyl, butylene, etc. The alkenyl group can be optionally substituted or unsubstituted.

[0085] "Alkynyl" refers to a linear or branched monovalent hydrocarbon group of 2-12 carbon atoms, or 2-8 carbon atoms, or 2-6 carbon atoms, or 2-4 carbon atoms, wherein at least one CC is a sp triple bond, wherein the alkynyl group may be independently optionally substituted with one or more substituents described herein, specific examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc. Alkynyl may be optionally substituted or unsubstituted.

[0086] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring includes 3 to 20 carbon atoms, preferably includes 3 to 12 carbon atoms, more preferably includes 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes cycloalkyl of spiro ring, condensed ring and bridge ring. Cycloalkyl can be optionally substituted or unsubstituted.

[0087] "Spirocycloalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and one carbon atom (called spiro atom) shared between the monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of spiro atoms shared between the rings, the spirocycloalkyl is divided into single spiro, double spiro or multi-spirocycloalkyl, preferably single spiro and double spirocycloalkyl, preferably 4 / 5 members, 4 / 6 members, 5 / 5 members or 5 / 6 members. Non-limiting examples of "spirocycloalkyl" include, but are not limited to:

[0088]

[0089] "Fused cycloalkyl" refers to a 5 to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of "fused cycloalkyl" include, but are not limited to:

[0090]

[0091] "Bridged cycloalkyl" refers to a 5 to 18-membered, all-carbon polycyclic group containing two or more cyclic structures, sharing two carbon atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to:

[0092]

[0093] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.

[0094] "Alkylene" refers to a divalent alkyl group or a divalent cycloalkyl group (cycloalkylene), wherein the divalent alkyl group is preferably a divalent alkyl group of 1-10 carbon atoms, more preferably a divalent alkyl group of 1-6 carbon atoms, and particularly preferably a divalent alkyl group of 1-4 carbon atoms; wherein the cycloalkylene group is preferably a cycloalkylene group of 3-12 carbon atoms, more preferably a cycloalkylene group of 3-8 carbon atoms, and most preferably a cycloalkylene group of 3-6 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene, ethylene, -CH(CH3)-, -CH(CH3)2-, n-propylene, cyclopropylene, cyclobutylene, cyclopentylene, etc. Alkylene groups may be substituted or unsubstituted.

[0095] "Heterocyclyl", "heterocycle" or "heterocyclic" are used interchangeably in this application and refer to a saturated or partially unsaturated monocyclic, bicyclic or tricyclic non-aromatic heterocyclic group containing 3-12 ring atoms, wherein at least one ring atom is a heteroatom, such as an oxygen, nitrogen, sulfur atom, etc. Preferably, it has a 5-7 membered monocyclic ring or a 7-10 membered bi- or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and / or sulfur. Examples of "heterocyclyl" include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl. The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is the heterocyclyl. The heterocyclyl may be optionally substituted or unsubstituted.

[0096] "Spiro heterocyclyl" refers to a polycyclic group with 5 to 18 members, two or more ring structures, and the single rings share one atom with each other, containing one or more double bonds in the ring, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen, sulfur or S(O) m The heteroatom of the ring is 6 to 14, and the remaining ring atoms are carbon. Preferably, it is 6 to 14, and more preferably 7 to 10. According to the number of spiro atoms shared between rings, the spiro heterocyclic group is divided into a monospiro heterocyclic group, a bispiro heterocyclic group or a polyspiro heterocyclic group, preferably a monospiro heterocyclic group and a bispiro heterocyclic group. More preferably, it is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiro heterocyclic group. Non-limiting examples of "spiro heterocyclic group" include, but are not limited to:

[0097]

[0098] "Fused heterocyclic group" refers to an all-carbon polycyclic group containing two or more ring structures sharing a pair of atoms, one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen, sulfur or S(O) m The heteroatom of the ring is 6 to 14, and the remaining ring atoms are carbon. It is preferably 6 to 14, and more preferably 7 to 10. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, and more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of "fused heterocyclic group" include, but are not limited to:

[0099]

[0100] "Bridged heterocyclic group" refers to a polycyclic group of 5 to 18 members, containing two or more ring structures, sharing two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen, sulfur or S(O) m The heteroatom of the cyclic group is 6 to 14, and the remaining ring atoms are carbon. It is preferably 6 to 14, and more preferably 7 to 10. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclic groups" include, but are not limited to:

[0101]

[0102] "Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be linked together in a fused manner. The term "aryl" includes aromatic groups such as phenyl, naphthyl, tetrahydronaphthyl. Preferably, aryl is C6-C 10 Aryl, more preferably phenyl and naphthyl, most preferably phenyl. Aryl can be substituted or unsubstituted. The "aryl" can be fused with heteroaryl, heterocyclic or cycloalkyl, wherein the aryl ring is connected to the parent structure, non-limiting examples include but are not limited to:

[0103]

[0104] "Heteroaryl" refers to an aromatic 5 to 6-membered monocyclic or 9 to 10-membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and / or sulfur. The embodiment of "heteroaryl" includes, but is not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolyl, indazolyl, benzisothiazolyl, benzoxazolyl and benzisoxazolyl. Heteroaryl may be optionally substituted or unsubstituted. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples include but are not limited to:

[0105]

[0106] "Alkoxy" refers to a group of (alkyl-O-). Wherein, alkyl is as defined herein. C1-C6 alkoxy is preferred. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, etc.

[0107] "Haloalkyl" refers to an alkyl group having one or more halogen substituents, wherein the alkyl group has the meaning as described herein. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, 1,1-dichloroethyl, 1,2-dichloropropyl, and the like.

[0108] "Hydroxy" refers to an -OH group.

[0109] "Halogen" refers to fluorine, chlorine, bromine and iodine.

[0110] "Amino" refers to -NH2.

[0111] "Cyano" refers to -CN.

[0112] "Nitro" refers to -NO2.

[0113] "Benzyl" refers to -CH2-phenyl.

[0114] "Carboxy" refers to -C(O)OH.

[0115] "Acetyl" refers to -C(O)CH3 or Ac.

[0116] "Tf" refers to trifluoromethanesulfonyl;

[0117] “Ms” means methanesulfonyl;

[0118] "Borate" refers to -B(OH)2;

[0119] "Borate ester group" refers to -B[O(alkyl) or (cycloalkyl)][O(alkyl) or (cycloalkyl)], or two alkyl groups and the connected O atom may further form a 5- to 6-membered heterocyclic group, and the 5- to 6-membered heterocyclic group may be further substituted;

[0120] "Carboxylate" refers to -C(O)O(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.

[0121] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.

[0122] The term "substituted" or "substituted" as used herein, unless otherwise specified, means that a group may be substituted by one or more groups selected from the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =O, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 , where R 2 , R 3 and R 4 The definition of is as described in the general formula (I).

[0123] The definitions and conventions used in this invention for stereochemistry are generally based on the following references:

[0124] SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric centers or chiral centers, and therefore exist in different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to, diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, constitute part of the present invention. Diastereomers can be separated into individual diastereomers based on their physical and chemical differences by methods such as chromatography, crystallization, distillation or sublimation. Enantiomers can be separated to convert a chiral isomeric mixture into a diastereomeric mixture by reacting with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers into the corresponding pure enantiomers. The intermediates and compounds of the present invention may also exist in different tautomeric forms, and all such forms are included within the scope of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D, L or R, S are used to indicate the absolute configuration of the chiral center of the molecule. The prefixes d, l or (+), (-) are used to name the sign of rotation of the plane of polarized light of the compound, (-) or l means that the compound is left-handed, and the prefix (+) or d means that the compound is right-handed. These stereoisomers have the same order of attachment of atoms or groups of atoms to each other, but their stereostructures are different. Specific stereoisomers may be enantiomers, and mixtures of isomers are usually called enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in no stereoselectivity or stereospecificity during chemical reactions. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lacks optical activity.

[0125] "Tautomers" or "tautomeric forms" refer to structural isomers of different energies that can be interconverted through a low energy barrier. For example, proton tautomers (i.e., prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. Valence (chemical valence) tautomers include interconversions by reorganization of bonding electrons. Unless otherwise indicated, the structural formulas described in the present invention include all isomeric forms (such as enantiomers, diastereomers, and geometric isomers): for example, R, S configurations containing asymmetric centers, (Z), (E) isomers of double bonds, and (Z), (E) conformational isomers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers are all within the scope of the present invention.

[0126] Synthesis method of the compound of the present invention

[0127] In order to achieve the purpose of the present invention, the present invention adopts the following technical scheme:

[0128] The present invention provides a method for preparing a compound of the general formula (ID) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, comprising the following steps:

[0129]

[0130] The compound of general formula (IB) and the compound of general formula (IC) undergo coupling reaction in the presence of a palladium catalyst to obtain a compound of general formula (ID);

[0131] in:

[0132] R d is selected from a boronic acid group or a boronic ester group; the boronic ester group is preferably:

[0133]

[0134] G is a leaving group, preferably selected from halogen or trifluoromethanesulfonyloxy; halogen is more preferably Cl or Br;

[0135] PG is a protecting group for N, preferably tert-butoxycarbonyl;

[0136] The palladium catalyst is [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride or tetrakis(triphenylphosphine)palladium;

[0137] L1, L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in general formula (I).

[0138] The present invention provides a method for preparing a compound of general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, comprising the following steps:

[0139]

[0140] The compound of formula (ID) is further deprotected by PG to obtain a compound of formula (IA); the compound of formula (IA) is reacted with E-(alkylene)-OMs, EC(O)X, E-(alkylene)-C(O)X or EC(O)H to obtain the compound of formula (I);

[0141] in:

[0142] PG is a protecting group for N, preferably tert-butoxycarbonyl;

[0143] X is selected from hydroxyl or halogen, preferably hydroxyl, Cl or Br;

[0144] L1, L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in general formula (I). DETAILED DESCRIPTION

[0145] The present invention is further described below with reference to the embodiments, but these embodiments are not intended to limit the scope of the present invention.

[0146] Example

[0147] The examples provide the preparation of representative compounds represented by formula (I) and related structural identification data. It must be noted that the following examples are used to illustrate the present invention rather than to limit the present invention. 1 H NMR spectra were obtained using a Bruker instrument (400 MHz) and chemical shifts are expressed in ppm. Tetramethylsilane was used as an internal standard (0.00 ppm). 1H NMR notation: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplet. Coupling constants, when provided, are in Hz.

[0148] The mass spectrum is obtained by LC / MS, and the ionization method can be ESI or APCI.

[0149] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.

[0150] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0151] In the following examples, unless otherwise indicated, all temperatures are in degrees Celsius. Unless otherwise indicated, various starting materials and reagents are commercially available or synthesized according to known methods. Commercially available materials and reagents are used directly without further purification. Unless otherwise indicated, commercial manufacturers include but are not limited to Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Guangzan Chemical Technology Co., Ltd. and Jingyan Chemical Technology Co., Ltd.

[0152] CD3OD: deuterated methanol

[0153] CDCl3: deuterated chloroform

[0154] DMSO-d6: deuterated dimethyl sulfoxide

[0155] Argon atmosphere means that the reaction bottle is connected to an argon balloon with a capacity of about 1L.

[0156] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution.

[0157] The compound is purified by silica gel column chromatography and thin layer chromatography, wherein the eluent or developing solvent system is selected from: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: dichloromethane: ethyl acetate; wherein the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or alkaline reagents, such as acetic acid or triethylamine, can also be added for adjustment.

[0158] Example 1

[0159] 4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0160] 4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 1

[0161]

[0162] first step

[0163] tert-butyl 5-bromo-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate

[0164] Tert-butyl 5-bromo-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1c

[0165] Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate 1a (5 g, 16.18 mmol, prepared by the method disclosed in patent application "WO2003092686") was added to a 250 mL three-necked flask, and 5-bromo-2-iodopyridine 1b (4.58 g, 16.18 mmol), dioxane (162 mL), water (20 mL), sodium carbonate (5.15 g, 48.54 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (1.18 g, 1.62 mmol) were added in sequence. The reaction solution was heated to 80 °C and reacted for 4 hours. The reaction solution was cooled to room temperature, dioxane was spin-dried, 150 mL of water was added, extracted with ethyl acetate (50 mL×3), washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to obtain tert-butyl 5-bromo-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1c (2.82 g, white solid) with a yield of 54%.

[0166] MS m / z(ESI):339.1[M+1]

[0167] Step 2

[0168] (1'-(tert-butoxycarbonyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)boronic acid

[0169] (1'-(tert-Butyloxycarbonyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)boronic acid 1d

[0170] Tert-butyl 5-bromo-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1c (2.82 g, 8.3 mmol) was added into a 250 mL three-necked flask, and then diboric acid pinacol ester (2.54 g, 10 mmol), 100 mL of dioxane, 15 mL of water, potassium acetate (2.44 g, 24.9 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (607 mg, 0.83 mmol) were added in sequence. The reaction solution was heated to 100 °C and reacted for 7 hours. The reaction solution was cooled to room temperature, dioxane was spin-dried, 150 mL of water was added, extracted with ethyl acetate (40 mL×3), washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: C system) to obtain (1'-(tert-butoxycarbonyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)boronic acid 1d (936 mg, light brown solid) with a yield of 37%.

[0171] MS m / z(ESI):305.1[M+1]

[0172] Step 3

[0173] tert-butyl

[0174] 5-(3-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine

[0175] ]-1'(2'H)-carboxylate

[0176] Tert-butyl 5-(3-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1f

[0177] (1'-(tert-Butyloxycarbonyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)boric acid 1d (100 mg, 0.33 mmol) was added to a 50 mL three-necked flask, and 3-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate 1e (146 mg, 0.39 mmol, prepared by the method disclosed in patent application "WO2017011776"), 5 mL of dioxane, 15 mL of water, sodium carbonate (70 mg, 0.66 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (24 mg, 0.03 mmol) were added in sequence, and the reaction solution was heated to 100 °C for 6 hours. The reaction solution was cooled to room temperature, the dioxane was spin-dried, 30 mL of water was added, extracted with ethyl acetate (20 mL×3), washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to obtain tert-butyl 5-(3-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1f (97 mg, light yellow solid) with a yield of 61%.

[0178] MS m / z(ESI):481.6[M+1]

[0179] Step 4

[0180] 6-(1-methyl-1H-pyrazol-4-yl)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)pyrazolo[1,5-a]pyridine-

[0181] 3-carbonitrile

[0182] 6-(1-methyl-1H-pyrazol-4-yl)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 1g

[0183] Tert-butyl 5-(3-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 1f (650 mg, 1.35 mmol) was added to a 50 mL single-mouth bottle, and a 4N hydrochloric acid / dioxane solution (10 mL) was added, and the reaction solution was heated to 30°C for 4 hours. The reaction solution was concentrated under reduced pressure to obtain 6-(1-methyl-1H-pyrazol-4-yl)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 1g (514.8 mg, yellow solid), which was directly used in the next step.

[0184] MS m / z(ESI):381.4[M+1]

[0185] Step 5

[0186] 4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0187] 4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 1

[0188] 1 g (100 mg, 0.26 mmol) of 6-(1-methyl-1H-pyrazol-4-yl)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was added into a 25 mL single-necked bottle, and 5 mL of N,N-dimethylformamide, N,N-diisopropylethylamine (339 mg, 2.62 mmol), and (6-methoxypyridin-3-yl)methyl methanesulfonate 1h (171 mg, 0.79 mmol, prepared by the method disclosed in patent application "WO2014066659") were added in sequence. The reaction solution was heated to 70 ° C and reacted for 6 hours. The reaction solution was cooled to room temperature, 50 mL of ethyl acetate was added, washed with water (20 mL×3) and saturated sodium chloride solution (20 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by thin layer chromatography (eluent: System B) to give 4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 1 (34 mg, light yellow solid) with a yield of 25%.

[0189] MS m / z(ESI):503.3[M+1]

[0190] 1 H NMR (400MHz, DMSO): δ9.32(d,J=1.4Hz,1H),8.79(d,J=1.9Hz,1H),8.68(s,1H),8.41(s,1H),8.14(s,1H),8.11(s,1H),8.07-8.03(m,1H),7.9 2(d,J=1.4Hz,1H),7.70(d,J=8.2Hz,2H),6.85-6.79(m,2H),3.88(s,3 H),3.85(s,3H),3.58(s,2H),3.17(d,J=5.3Hz,2H),2.70-2.61(m,4H).

[0191] Example 2

[0192] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0193] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 2

[0194]

[0195] first step

[0196] 4-(6-chloropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0197] 4-(6-Chloropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 2c

[0198] 4-Bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 2a (1.6 g, 5.12 mmol, prepared by the method disclosed in patent application "WO2018071447") was added to a 100 mL three-necked flask, and 35 mL of N,N-dimethylformamide, 2-chloropyridine-5-boric acid pinacol ester 2b (1.6 g, 6.7 mmol), potassium phosphate (5.7 g, 27.1 mmol) and tetrakis(triphenylphosphine)palladium (0.295 g, 0.26 mmol) were added in sequence, and the reaction solution was heated to 95 ° C for 16 hours. The reaction solution was cooled to room temperature, 70 mL of water was added, extracted with a mixture of dichloromethane and methanol (V:V=10:1, 100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to give 4-(6-chloropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 2c (1.26 g, yellow solid) with a yield of 72%.

[0199] MS m / z(ESI):343.0[M+1]

[0200] Step 2

[0201] tert-butyl5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridi

[0202] ne]-1'(2'H)-carboxylate

[0203] Tert-butyl 5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 2e

[0204] In a 25 mL microwave tube, 12 mL of 1,4-dioxane, 3 mL of water, 4-(6-chloropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 2c (0.5 g, 1.46 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid methyl ester 2d (0.74 g, 2.39 mmol), sodium carbonate (0.419 g, 3.9 mmol) and tetrakis(triphenylphosphine)palladium (0.2 mg, 0.13 mmol) were added in sequence, and the reaction solution was heated to 110°C and microwaved for 1.5 hours. The reaction solution was cooled to room temperature, 30 mL of water was added, extracted with ethyl acetate (30 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to obtain tert-butyl 5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 2e (460 mg, yellow solid) with a yield of 62.6%.

[0205] MS m / z(ESI):490.0[M+1]

[0206] Step 3

[0207] 6-(2-hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)pyrazolo[1,5-a]pyridin

[0208] e-3-carbonitrile hydrogen chloride

[0209] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride

[0210] 2f

[0211] (tert-Butyl 5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 2e (460 mg, 0.94 mmol) was added to a 100 mL three-necked flask, and 30 mL of dichloromethane and 10 mL of 4N hydrochloric acid / dioxane solution were added in sequence. The reaction solution was reacted at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure to obtain 6-(2-hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (441 mg, light yellow solid), which was directly used in the next step.

[0212] MS m / z(ESI):390.0[M+1]

[0213] Step 4

[0214] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-b

[0215] ipyridin]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0216] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 2

[0217] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (120 mg, 0.31 mmol) was added to a 10 mL three-necked flask, and 3 mL of acetonitrile, cesium carbonate (200 mg, 0.61 mmol), and 5-(chloromethyl)-2-methoxypyridine 2g (148 mg, 0.86 mmol, prepared by the method disclosed in patent application "WO2016033445") were added in sequence. The reaction solution was heated to 75 ° C and reacted for 1.5 hours. The reaction solution was cooled to room temperature, 100 mL of water was added, the mixture was stirred and filtered, the filter cake was dissolved in ethyl acetate (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was recrystallized from acetonitrile to give 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((6-methoxypyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 2 (50 mg, gray solid) with a yield of 33.3%.

[0218] MS m / z(ESI):511.2[M+1]

[0219] 1 H NMR (400MHz, DMSO): δ12.24-12.19(m,1H),8.75(dd,J=8.2,2.1Hz,2H),8.60(s,1H),8.11(d,J=2.0Hz,1H),7.99(dt,J=15.9,7.9Hz,1H) ,7.73-7.63(m,2H),7.44(d,J=2.0Hz,1H),6.81(t,J=5.7Hz,2H),4.72(s,1H),3.89(s,2H),3.85(s,3H),3.57(s,2H),3.15(d,J=2.4Hz,

[0220] 2H),2.67(d,J=4.9Hz,2H),2.62(s,2H),1.23(s,6H).

[0221] Example 3

[0222] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((5-methoxypyridin-2-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-b

[0223] ipyridin]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0224] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-((5-methoxypyridin-2-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0225]

[0226] first step

[0227] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((5-methoxypyridin-2-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-b

[0228] ipyridin]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0229] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-((5-methoxypyridin-2-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 3

[0230] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (78 mg, 0.175 mmol) was added to a 10 mL three-necked flask, and 3 mL of acetonitrile, triethylamine (202 mg, 2 mmol), and (5-methoxypyridin-2-yl)methyl methanesulfonate 3a (176 mg, 0.8 mmol, prepared by the method disclosed in patent application "WO2018130838") were added in sequence. The reaction solution was heated to 70 ° C and reacted for 2 hours. The reaction solution was cooled to room temperature, 100 mL of water was added, the mixture was stirred and filtered, the filter cake was collected and purified by high performance liquid chromatography to give 6-(2-hydroxy-2-methylpropoxy)-4-(1'-((5-methoxypyridin-2-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 3 (36 mg, yellow solid) with a yield of 36%.

[0231] MS m / z(ESI):511.3[M+1]

[0232] 1 H NMR (400MHz, DMSO): δ8.80(dd,J=9.5,2.2Hz,2H),8.61(s,1H),8.42(d,J=2.3Hz,1H),8.09(dt,J=8.8,4.4Hz,1H),7.80(d,J=8.2Hz,1H),7.57(dt,J= 8.6,5.5Hz,2H),7.50-7.43(m,1H),6.85(s,1H),4.54(s,2H),4.00(s,2H), 3.90(d,J=2.3Hz,2H),3.89(s,3H),3.54(s,2H),2.95(s,2H),1.23(s,6H).

[0233] Example 4

[0234] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(4-methoxybenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)

[0235] pyrazolo[1,5-a]pyridine-3-carbonitrile

[0236] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-(4-methoxybenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]

[0237] Pyridine-3-carbonitrile

[0238]

[0239] first step

[0240] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(4-methoxybenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)

[0241] pyrazolo[1,5-a]pyridine-3-carbonitrile

[0242] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-(4-methoxybenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]

[0243] Pyridine-3-carbonitrile 4

[0244] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (78 mg, 0.175 mmol) was added into a 10 mL three-necked flask, and 3 mL of acetonitrile, triethylamine (121 mg, 1.2 mmol), and 4-methoxybenzyl methanesulfonate 4a (250 mg, 1 mmol, prepared by the method disclosed in patent application "US6194406") were added in sequence. The reaction solution was heated to 70 °C and reacted for 3 hours. The reaction solution was cooled to room temperature, 20 mL of water was added, extracted with a mixture of dichloromethane and methanol (V:V=10:1, 15 mL×3), concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography to give 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(4-methoxyphenyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 4 (10 mg, yellow solid) with a yield of 10%.

[0245] MS m / z(ESI):510.3[M+1]

[0246] 1 H NMR (400MHz, DMSO): δ12.24-12.18(m,1H),8.77(dd,J=8.2,2.1Hz,2H),8.65(s, 1H),8.08(d,J=2.0Hz,1H),8.0(dt,J=15.9,7.9Hz,1H),7.78-7.62(m,4H),7.44 -7.21(m,3H),6.83(t,J=5.7Hz,2H),4.71(s,1H),3.89(s,2H),3.84(s,3H),3.5 8(s,2H),3.14(d,J=2.4Hz,2H),2.77(d,J=4.9Hz,2H),2.69(s,2H),1.25(s,6H).

[0247] Example 5

[0248] 4-(1'-((5-fluoropyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0249] 4-(1'-((5-fluoropyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[2-hydroxy-2-methylpropoxy] ...

[0250] [1,5-a]Pyridine-3-carbonitrile 5

[0251]

[0252] first step

[0253] 4-(1'-((5-fluoropyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0254] 4-(1'-((5-fluoropyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[2-hydroxy-2-methylpropoxy] ...

[0255] [1,5-a]Pyridine-3-carbonitrile 5

[0256] (5-Fluoropyridin-3-yl)methyl methanesulfonate 5a (150 mg, 0.73 mmol, prepared by the method disclosed in patent application "US20080153883") was dissolved in 5 mL of acetonitrile, and 6-(2-hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (95 mg, 0.24 mmol) and triethylamine (73 mg, 0.72 mmol) were added, and the temperature was raised to 70 ° C for 2 hours. The reaction was complete after TLC detection, and 5 mL of water was added to quench the reaction. The reaction was extracted with ethyl acetate (5 mL×3), washed with saturated sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by HPLC to give 4-(1'-((5-fluoropyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 5 (10 mg, red solid) with a yield of 2.7%.

[0257] MS m / z(ESI):498.8[M+1]

[0258] 1H NMR (400MHz, DMSO): δ8.81(d,J=2.0Hz,1H),8.78(d,J=2.0Hz,1H),8.73(d,J=2.8H z,1H),8.66(s,1H),8.61(s,1H),8.10(dd,J=2.4,8.0Hz,1H),7.99(ddd,J=2.4,1. 6,9.6Hz,1H),7.81(d,J=8.4Hz,1H),7.46(d,J=2.4Hz,1H),6.85(s,1H),4.58(s,2 H),3.98(s,2H),3.90(s,2H),3.73(s,1H),3.30(s,1H),3.00(t,2H),1.23(s,6H).

[0259] Example 6

[0260] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-(phenylthio)ethyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0261] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-(2-(phenylthio)ethyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0262]

[0263] first step

[0264] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-(phenylthio)ethyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-

[0265] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-(phenylthio)ethyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0266] Pyridine-3-carbonitrile 6

[0267] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (78 mg, 0.175 mmol) was added to a 10 mL three-necked flask, and 3 mL of acetonitrile, triethylamine (121 mg, 1.2 mmol), and 2-(phenylthio)ethyl methanesulfonate 6a (93 mg, 0.4 mmol, prepared by the method disclosed in patent application "JP2017137276") were added in sequence, and the reaction solution was heated to 70 ° C for 5 hours. The reaction solution was cooled to room temperature, 20 mL of water was added, stirred and filtered, and the filter cake was purified by high performance liquid chromatography to obtain 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-(phenylthio)ethyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 6 (30 mg, white solid) with a yield of 30%. MS m / z (ESI): 526.3 [M+1]

[0268] 1 H NMR (400MHz, DMSO): δ8.75 (dd, J=6.4, 2.0Hz, 2H), 8.60 (s, 1H), 8.01 (dd, J=8. 2,2.3Hz,1H),7.70(d,J=8.3Hz,1H),7.45(d,J=2.0Hz,1H),7.34(dt,J=15.3, 7.6Hz,4H),7.19(t,J=7.0Hz,1H),6.83(s,1H),4.71(s,1H),3.90(s,2H),3.2 5(s,2H),3.22-3.15(m,2H),2.70(d,J=6.5Hz,4H),2.62(s,2H),1.23(s,6H).

[0269] Example 7

[0270] 4-(1'-(3,5-difluorobenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(2-hydroxy-2-methylpropox

[0271] y)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0272] 4-(1'-(3,5-difluorobenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]

[0273] Pyridine-3-carbonitrile 7

[0274]

[0275] first step

[0276] 4-(1'-(3,5-difluorobenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5-yl)-6-(2-hydroxy-2-methylpropox

[0277] y)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0278] 4-(1'-(3,5-difluorobenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]

[0279] Pyridine-3-carbonitrile 7

[0280] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (78 mg, 0.175 mmol) was added to a 10 mL three-necked flask, and 3 mL of acetonitrile, triethylamine (121 mg, 1.2 mmol), and 3,5-difluorobenzyl methanesulfonate 7a (88 mg, 0.4 mmol, prepared by the method disclosed in patent application "WO2012092442") were added in sequence. The reaction solution was heated to 70 ° C and reacted for 5 hours. The reaction solution was cooled to room temperature, 20 mL of water was added, stirred and filtered, and the filter cake was purified by high performance liquid chromatography to obtain 4-(1'-(3,5-difluorobenzyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile 7 (50 mg, white solid) with a yield of 50%. MS m / z (ESI): 516.3 [M+1]

[0281] 1H NMR (400MHz, DMSO): δ8.80(dd,J=10.8,2.1Hz,2H),8.61(s,1H),8.10(dd,J=8.3,2.3Hz,1H),7.81(d,J=8.2Hz,1H),7.47(d,J=2.1Hz,1H),7.46-7.39( m,1H),7.37(d,J=6.1Hz,2H),6.84(s,1H),4.50(s,2H),3.95(s,2H),3.90( s,2H),3.57(dd,J=122.6,40.4Hz,2H),2.95(d,J=49.9Hz,2H),1.23(s,6H)

[0282] Example 8

[0283] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(6-methoxynicotinoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5

[0284] -yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0285] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-(6-methoxynicotinoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[2-(2-hydroxy ...

[0286] [1,5-a]Pyridine-3-carbonitrile 8

[0287]

[0288] first step

[0289] 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(6-methoxynicotinoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]-5

[0290] -yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0291] 6-(2-Hydroxy-2-methylpropoxy)-4-(1'-(6-methoxynicotinoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[2-(2-hydroxy ...

[0292] [1,5-a]Pyridine-3-carbonitrile 8

[0293] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (39 mg, 0.087 mmol) was added to a 10 mL three-necked flask, and 2 mL N,N-dimethylformamide, 6-methoxynicotinic acid 8a (30 mg, 0.196 mmol), 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate (38 mg, 0.1 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol), stirred at room temperature for 16 hours, added 30 mL of water, stirred and filtered, and the filter cake was purified by high performance liquid chromatography to obtain 6-(2-hydroxy-2-methylpropoxy)-4-(1'-(6-methoxynicotinoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 8 (21 mg, white solid), with a yield of 40%. MS m / z (ESI): 522.2 [M+1]

[0294] 1 H NMR (400MHz, DMSO): δ8.80-8.75(m,2H),8.61(s,1H),8.35(d,J=2.0Hz,1H),8.06(dd,J=8.3,2.3Hz,1H),7.85(dd,J=8.5,2.4Hz,1H),7.74(d,J=8. 1Hz,1H),7.46(d,J=2.0Hz,1H),6.92(s,1H),6.90(s,1H),4.32(s,2H),3. 91(s,3H),3.90(s,2H),3.69(d,J=28.5Hz,2H),2.74(s,2H),1.23(s,6H).

[0295] Example 9

[0296] (R)-6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-phenylpropanoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]

[0297] -5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0298] (R)-6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-phenylpropanoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[2 ...

[0299] [1,5-a]Pyridine-3-carbonitrile 9

[0300]

[0301] Step 1 (R)-6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-phenylpropanoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridin]

[0302] -5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0303] (R)-6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-phenylpropanoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridinyl]-5-yl)pyrazolo[2 ...

[0304] [1,5-a]Pyridine-3-carbonitrile 9

[0305] 6-(2-Hydroxy-2-methylpropoxy)-4-(1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride 2f (39 mg, 0.087 mmol) was added to a 10 mL three-necked flask, and 2 mL N,N-dimethylformamide, (R)-2-phenylpropionic acid 9a (30 mg, 0.2 mmol), 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate (38 mg, 0.1 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol), stirred at room temperature for 16 hours, 30 mL of water was added, stirred and filtered, and the filter cake was purified by high performance liquid chromatography to obtain 6(R)-6-(2-hydroxy-2-methylpropoxy)-4-(1'-(2-phenylpropanoyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 9 (21 mg, white solid), with a yield of 40%.

[0306] MS m / z(ESI):522.2[M+1]

[0307] 1H NMR (400MHz, DMSO): δ8.81-8.69(m,2H),8.61(d,J=13.6Hz,1H),8.03-7.98(m,1H),7. 66(t,J=9.4Hz,1H),7.43(d,J=1.8Hz,1H),7.32(t,J=7.0Hz,4H),7.23(t,J=6.6Hz,1H) ,6.77(d,J=43.6Hz,1H),4.37(dd,J=43.8,17.1Hz,3H),4.25-4.11(m,2H),3.89(s,2H ),3.70-3.57(m,2H),2.00(dd,J=15.0,7.3Hz,1H),1.33(d,J=6.7Hz,3H),1.23(s,6H).

[0308] Example 10

[0309] 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0310] 6-(3-Hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10

[0311]

[0312]

[0313] first step

[0314] methyl(E)-3-(3-cyano-4-methoxypyrazolo[1,5-a]pyridin-6-yl)acrylate

[0315] (E)-3-(3-cyano-4-methoxypyrazolo[1,5-a]pyridin-6-yl)acrylate methyl ester 10b

[0316] 6-Bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile 10a (2.52 g, 10 mmol, prepared by the method disclosed in patent application "WO2017011776"), methyl acrylate (3.2 mL, 35 mmol), triethylamine (3.75 mL, 27 mmol), tri(o-methylphenyl)phosphine (0.51 g, 1.67 mmol), palladium acetate (0.25 g, 1.13 mmol) were added to 15 mL of acetonitrile, heated to reflux temperature under nitrogen protection, and reacted for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: C system) to obtain (E)-3-(3-cyano-4-methoxypyrazolo[1,5-a]pyridin-6-yl)methyl acrylate 10b (1.8 g, light yellow solid) with a yield of 70%.

[0317] MS m / z(ESI):258.1[M+1]

[0318] 1 H NMR (400MHz, DMSO): δ8.99(s,1H),8.65(s,1H),7.75(dd,J=16.0,9.9Hz,1H),7.45(s,1H),6.96(d,J=16.0Hz,1H),4.07(s,3H),3.76(s,3H).

[0319] Step 2

[0320] methyl(E)-3-(3-cyano-4-hydroxypyrazolo[1,5-a]pyridin-6-yl)acrylate

[0321] (E)-3-(3-cyano-4-hydroxypyrazolo[1,5-a]pyridin-6-yl)acrylate 10c

[0322] Methyl (E)-3-(3-cyano-4-methoxypyrazolo[1,5-a]pyridin-6-yl)acrylate 10b (1.54 g, 6.0 mmol) was added to 80 mL of 1,2-dichloroethane, and aluminum chloride (2.4 g, 18 mmol) was added, and the reaction solution was heated to 80°C for 4 hours. The reaction solution was cooled to room temperature, tetrahydrofuran (100 mL) and sodium sulfate decahydrate (10 g) were added to quench, stirred at room temperature overnight, filtered, and the filtrate was concentrated under reduced pressure to obtain methyl (E)-3-(3-cyano-4-hydroxypyrazolo[1,5-a]pyridin-6-yl)acrylate 10c (1.22 g, dark brown solid), which was directly subjected to the next step reaction.

[0323] MS m / z(ESI):244[M+1]

[0324] Step 3

[0325] methyl(E)-3-(3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)pyrazolo[1,5-a]pyridin-6-yl)acrylate

[0326] (E)-3-(3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10d

[0327] Methyl (E)-3-(3-cyano-4-hydroxypyrazolo[1,5-a]pyridin-6-yl)acrylate 10c (1.22 g, 5.0 mmol) was added to 10 mL of N,N-dimethylacetamide, and N-phenylbis(trifluoromethanesulfonyl)imide (3.57 g, 10.0 mmol) and N,N-diisopropylethylamine (1.7 mL, 5.0 mmol) were added, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate (200 mL) was added to the reaction solution, and the mixture was washed with water (50 mL×3) and saturated sodium chloride solution (50 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: C system) to obtain (E)-methyl 3-(3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10d (0.76 g, light yellow solid) with a yield of 40.4%.

[0328] MS m / z(ESI):376[M+1]

[0329] 1 H NMR (400MHz, DMSO): δ9.56 (s, 1H), 8.88 (s, 1H), 8.43 (s, 1H), 7.81 (d, J = 16.1Hz, 1H), 7.01 (d, J = 16.0Hz, 1H), 3.77 (s, 3H).

[0330] Step 4

[0331] methyl(E)-3-(3-cyano-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)acrylate

[0332] (E)-3-(3-cyano-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10e

[0333] Methyl (E)-3-(3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10d (751 mg, 2.0 mmol), 2-fluoropyridine-5-boronic acid pinacol ester (670 mg, 3.0 mmol), tetrakis(triphenylphosphine)palladium (116 mg, 0.1 mmol), 3 mL 2N sodium carbonate solution and 9 mL 1,2-dichloroethane were added to a 25 mL microwave tube, and the temperature was raised to 100°C for microwave reaction for 1.5 hours under nitrogen protection. The filter cake was filtered, washed with water (2 mL×5), and dried to obtain methyl (E)-3-(3-cyano-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10e (560 mg, light yellow solid), which was directly used for the next step.

[0334] MS m / z(ESI):323[M+1]

[0335] 1 H NMR (400MHz, DMSO): δ9.46 (s, 1H), 8.78 (s, 1H), 8.29 (d, J = 5.2Hz, 1H), 8.15 (s, 1H) ),7.83(d,J=16.2Hz,1H),7.49-7.37(m,2H),6.98(d,J=16.0Hz,1H),3.75(s,3H).

[0336] Step 5

[0337] tert-butyl

[0338] (E)-3-(5-(3-cyano-6-(3-methoxy-3-oxoprop-1-en-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6

[0339] -diazabicyclo[3.1.1]heptane-6-carboxylate

[0340] Tert-butyl (E)-3-(5-(3-cyano-6-(3-methoxy-3-oxoprop-1-en-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridine-2-yl

[0341] 1,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10f

[0342] Methyl (E)-3-(3-cyano-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)acrylate 10e (500 mg, 1.55 mmol) was added to 3 mL of dimethyl sulfoxide, tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (309 mg, 1.55 mmol) and potassium carbonate (1.1 g, 7.75 mmol), and the mixture was heated to 90°C and reacted for 20 hours. Ethyl acetate (100 mL) was added to the reaction solution, and the mixture was washed with water (30 mL×3) and a saturated sodium chloride solution (30 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: C system) to obtain tert-butyl (E)-3-(5-(3-cyano-6-(3-methoxy-3-oxoprop-1-en-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10f (250 mg, light yellow solid) with a yield of 32.3%.

[0343] MS m / z(ESI):501[M+1]

[0344] Step 6

[0345] tert-butyl

[0346] 3-(5-(3-cyano-6-(3-methoxy-3-oxopropyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicycl

[0347] o[3.1.1]heptane-6-carboxylate

[0348] Tert-butyl 3-(5-(3-cyano-6-(3-methoxy-3-oxopropyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10g

[0349] (E)-3-(5-(3-cyano-6-(3-methoxy-3-oxopropyl-1-en-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10f (180 mg, 0.36 mmol) was added to 5 mL of methanol and reacted at room temperature for 12 hours under a hydrogen atmosphere. The reaction solution was filtered and the filtrate was concentrated under reduced pressure to obtain tert-butyl 3-(5-(3-cyano-6-(3-methoxy-3-oxopropyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10g (171 mg, light yellow solid), which was directly subjected to the next step reaction.

[0350] MS m / z(ESI):503[M+1]

[0351] Step 7

[0352] tert-butyl

[0353] 3-(5-(3-cyano-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicy

[0354] clo[3.1.1]heptane-6-carboxylate

[0355] Tert-butyl 3-(5-(3-cyano-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo

[0356] [3.1.1] Heptane-6-carboxylate 10h

[0357] 10 g (150 mg, 0.3 mmol) of tert-butyl 3-(5-(3-cyano-6-(3-methoxy-3-oxopropyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate was added to 10 mL of anhydrous ether, and 3N methylmagnesium bromide (1.0 mL) was added dropwise at 0°C. After the addition was completed, the temperature was raised to room temperature and reacted for 2 hours. The reaction solution was diluted with ethyl acetate (100 mL), quenched with saturated ammonium chloride solution (30 mL), washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: C system) to give tert-butyl 3-(5-(3-cyano-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10h (50 mg, light yellow solid) with a yield of 33.%.

[0358] MS m / z(ESI):503[M+1]

[0359] Step 8

[0360] 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]

[0361] pyridine-3-carbonitrile

[0362] 4-(6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridine-3-yl

[0363] Acetonitrile 10i

[0364] Tert-butyl 3-(5-(3-cyano-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate 10h (50 mg, 0.1 mmol) was added to 1 mL of dichloromethane, and 4N hydrochloric acid / dioxane solution (1 mL) was added, and the mixture was reacted at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure to obtain 4-(6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10i (40 mg, yellow oil), which was directly used for the next step.

[0365] MS m / z(ESI):403[M+1]

[0366] Step 9

[0367] 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]hept

[0368] an-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0369] 6-(3-Hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10

[0370] 4-(6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbutyl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10i (40 mg, 0.1 mmol) was added to 2 mL of 1,2-dichloroethane, sodium triacetoxyborohydride (27.4 mg, 0.2 mmol) and 6-methoxy-3-pyridinecarboxaldehyde (63.6 mg, 0.3 mmol), and the mixture was reacted at room temperature for 12 hours. The reaction solution was diluted with ethyl acetate (100 mL), washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System B) to give 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10 (8 mg, light yellow solid) in a yield of 15.4%.

[0371] MS m / z(ESI):522[M+1]

[0372] 1H NMR (400MHz, DMSO): δ12.24-12.19(m,1H),8.75(dd,J=8.2,2.1Hz,2H),8.60(s,1H) ,8.11(d,J=2.0Hz,1H),7.99(dt,J=15.9,7.9Hz,1H),7.73-7.63(m,2H),7.44(d,J=2 .0Hz,1H),6.81(t,J=5.7Hz,2H),4.72(s,1H),3.89(s,2H),3.85(s,3H),3.15(d,J=2 .4Hz,2H),2.67(d,J=4.9Hz,2H),2.31-2.23(m,2H),1.32(s,6H),1.25-1.23(m,2H).

[0373] Biological evaluation

[0374] Test Example 1: Determination of the inhibitory activity of the compounds of the present invention on the proliferation of RET abnormal tumor cells (TT cells)

[0375] The following method is used to determine the inhibitory activity of the preferred compounds of the present invention on TT cells in vitro. TT cells are human thyroid medullary carcinoma cell lines containing RET C634W mutations. The cell lines were purchased from ATCC (Cat. No. CRL-1803). The cells were cultured in Ham's F-12K (Kaighn's) medium (purchased from Thermofisher, Gibco, catalog number 21127022) supplemented with 10% fetal bovine serum (FBS, purchased from Thermofisher, Gibco, catalog number 12483-020), 1x Glutamax (purchased from Thermofisher, Gibco, catalog number 35050061), 1x non-essential aminoacids (purchased from Thermofisher, Gibco, catalog number 11140050), 1x Pen / Strep antibiotics (purchased from Thermofisher, Gibco, catalog number 15140122) at 37°C and 5% CO2. Cell activity was measured by using Promega's CellTiter- The cells were detected using the Luminescent Cell Viability Assay (Cat. No. G7573).

[0376] The experimental method is briefly described as follows: On the day before the formal experiment, cells in the logarithmic growth phase were digested with trypsin (purchased from Thermofisher, Gibco, catalog number 25300054), and then an appropriate volume of culture medium was added to terminate the trypsin reaction. After centrifugation at 1000 rpm, the upper culture medium was aspirated and a new culture medium was added to prepare a cell suspension. 50uL of cell suspension was added to a 96-well cell culture plate (purchased from Corning, catalog number 3904), with a cell density of 6000 cells per well. The culture plate was then cultured overnight at 37°C and 5% CO2. On the day of the experiment, the test compound was first dissolved in DMSO (Sigma-Aldrich, catalog number v900090) to prepare a storage solution, and then serially diluted with DMSO at a ratio of 1:3, for a total of 9 concentration points, and a DMSO control was set at the same time. Then take another 96-well culture plate, add 250uL of serum-free F12 culture medium to each well, and then add 0.5uL of each concentration of compound solution to each well, shake and mix, and prepare the test sample. Then take 50uL of the test sample solution from each well and add it to the cell plate. The final test concentration range of the compound is 10000nM to 1.52nM, and each concentration contains a duplicate well control. The cell plate was cultured continuously for 8 days at 37°C and 5% CO2. After the culture is completed, 50uL of CellTiter-Glo reagent is added to each well, shake and mix, incubate at room temperature in the dark for 10 minutes, and then read the signal of each well on the Envision microplate reader (Perkin Elmer). Subsequently, nonlinear regression analysis was performed in the GraphPad Prism software using the logarithm of compound concentration-signal intensity to obtain the IC of the test compound for inhibiting cell proliferation. 50 value.

[0377] The inhibitory activity of the compounds of the present invention on the proliferation of RET abnormal tumor cells (TT cells) was determined by the above experiment, and the measured IC 50 See Table 1 for values

[0378] Table 1 IC inhibition of TT cell proliferation activity by compounds of the present invention 50

[0379] Compound No. <![CDATA[IC 50 (nM)]]> 1 28.9 8 87.8 10 68.6

[0380] Conclusion: The compounds of the present invention have a significant inhibitory effect on the proliferation of RET abnormal tumor cells (TT cells) Test Example 2: Determination of the inhibitory activity of the compounds of the present invention on RET enzyme

[0381] 1. Experimental Materials

[0382] Reagent name Suppliers Part Number GST-hRET kinase (658-1114) Carna 08-159 HTRF KinEASE-TK kit Cisbio 62TK0PEC 5X Enzyme Reaction Buffer Cisbio 62EZBFDC TK substrate-biotin Cisbio 61TK0BLE SEB Cisbio 61SEBALF Ultra Pure ATP Promega V915A TK Antibody-Cryptate Cisbio — streptavidin-XL665 Cisbio 610SAXLA Detection buffer Cisbio 62SDBRDD 384-well plate PerkinELmer 6007290

[0383] 2. Reagent preparation

[0384] (1) 1X enzyme reaction buffer: dilute 5x enzyme reaction buffer with ultrapure water in a ratio of 4:1 and add 25 nM SEB.

[0385] (2) 5X RET kinase: dilute RET kinase to 2.5 nM in 1X enzyme reaction buffer

[0386] (3) 5X ATP: 1X enzyme reaction buffer dilutes ATP to 50uM

[0387] (4) 5X substrate: dilute TK substrate-biotin to 2500nM in 1X enzyme reaction buffer

[0388] (5) 2.5X compound: the highest final concentration is 2500 nm, 3-fold gradient dilution, 10 dilution points, the final DMSO concentration is 0.4%

[0389] (6) 4X Steptavidin-XL665: dilute Steptavidin-XL665 to 250uM in 1X enzyme reaction buffer

[0390] 3. Experimental process

[0391] (1) Add 2ul / well of 5X RET kinase (final concentration 0.5nM) to a 384-well plate and set up a blank group (enzyme reaction buffer) as a negative control

[0392] (2) Add 4ul / well of 2.5X compound gradient and incubate at room temperature for 30 minutes. Set the DMSO group as the positive control

[0393] (3) Add 2ul / well 5X substrate (final concentration 500nM) and 2ul / well 5X ATP (final concentration 10uM) to start the reaction and react at room temperature for 30 minutes

[0394] (4) Add 5ul / well TK Antibody-Cryptate and 5ul / well 4X Steptavidin-XL665 (final concentration 62.5uM) and incubate at room temperature for 60 minutes

[0395] (5) Envision reads HTRF signals

[0396] 4. Data Analysis

[0397] Graph Pad prism software was used to analyze the dose effects (IC 50 ) for analysis

[0398] Table 1 IC inhibition of RET enzyme activity by compounds of the present invention 50

[0399] Compound No. <![CDATA[IC 50 (nM)]]> 1 23.1 2 25.4 10 5.6

[0400] Conclusion: The compounds of the present invention have a significant inhibitory effect on RET enzyme activity.

Claims

1. A compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof: in: Ring A is selected from the group: X 1 , X 2 Each independently selected from CH, CCH3, CF, CCl or N; X 3 , X 4 are each independently selected from CH, CF or N; Where X 1 , X 2 , X 3 and X 4 0, 1 or 2 of them are N; L1 is selected from a bond, -(R a R b C)-、-(R a R b N)-or-O-; L2 is selected from a bond, -(alkylene)-, -C(O)-, -S(O)-, -SO2-, -(alkylene)-O-, -(alkylene)-S-, -(alkylene)-NR 1 -, -C(O)-(alkylene)-, -SO2-(alkylene)-; wherein the right key of the L2 group is connected to E; wherein the alkylene group is optionally further substituted with one or more selected from hydroxyl, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 substituted by a substituent; R a is selected from a hydrogen atom, an alkyl group or a halogen; R b is selected from a hydrogen atom, an alkyl group or a halogen; Or, R a and R b Together with the C or N atom to which it is connected, it forms a 3-6-membered cycloalkyl or heterocyclic group, wherein the heterocyclic group contains one or more N, O, S(O) n Atoms, wherein the cycloalkyl or heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 substituted by a substituent; B is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from R c substituted by a substituent; E is selected from hydrogen, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl; wherein the cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -SO2NR 2 R 3 substituted by a substituent; preferably phenyl or pyridyl; R c is selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 2 R 3 、-C(O)NR 2 R 3 、-C(O)R 4 、-OC(O)R 4 、-NR 2 C(O)R 3 or -S(O)2NR 2 R 3 wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R 6 or -SO2NR 5 R 6 substituted by a substituent; R 1 are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group, an alkyl group, a halogen group or an alkoxy group, wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group or an alkoxy group; R 2 , R 3 and R 4 Each is independently selected from a hydrogen atom, a hydroxyl group, a halogen, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, a halogen, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R 6 or -SO2NR 5 R 6 substituted by a substituent; Or, R 2 and R 3 Together with the connected N atom, it forms a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic ring contains one or more N, O, S(O) n atom, and the 4- to 8-membered heterocyclic ring is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -NR 5 R 6 、-C(O)NR 5 R 6 、-C(O)R 7 、-OC(O)R 7 、-NR 5 C(O)R 6 or -SO2NR 5 R 6 substituted by a substituent; R 5 , R 6 and R 7 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group; m is selected from 0, 1, 2, 3, 4 or 5; n is selected from 0, 1 or 2; Provided that, when ring A is selected from the group: hour, (1) L1 is selected from -(R a R b C)-,-(R a R b N)-or-S-; (2) When L1 is selected from one group, B is selected from alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more selected from R c substituted by a substituent.

2. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound represented by general formula (III) or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof: in: (1) L1 is selected from -(R a R b C)-、-(R a N)-or-S-; Preferably, R a and R b is selected from a hydrogen atom or a methyl group; (2) When L1 is selected from a bond, B is selected from alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more selected from R c substituted by a substituent; L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 , R a , R b , R c and m are as defined in claim 1.

3. The compound according to any one of claims 1 to 2, or its stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 , X 2 , X 3 , X 4 is selected from CH or N; X 1 , X 2 , X 3 and X 4 0, 1 or 2 of them are N; Preferably, X 1 N, X 2 , X 3 , X 4 For CH.

4. The compound according to any one of claims 1 to 2, or its stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: L2 is selected from a bond, -(alkylene)-, -C(O)-, -SO2-, -(alkylene)-O-, -(alkylene)-S-, -(alkylene)-NR 1 - or -C(O)-(alkylene)-, wherein the right bond of the L2 group is connected to E; Preferably -(alkylene)-, -C(O)-, -(alkylene)-S- or -C(O)-(alkylene)-; The -(alkylene)- is preferably -(methylene)- or -CH(CH3)-.

5. The compound according to any one of claims 1 to 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein B is selected from: (i) a 5- to 6-membered heteroaryl group, wherein the heteroaryl group is optionally further substituted by one or more substituents selected from alkyl or halogen; Preferably, B is selected from pyrazolyl, wherein the pyrazolyl is optionally further substituted with methyl; (ii) an alkyl group, wherein the alkyl group is optionally further substituted with one or more hydroxyl groups; preferably, B is selected from the group: (iii) alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally further substituted with one or more hydroxyl groups; Preferably, when L1 is a bond, B is selected from the group consisting of:

6. The compound according to any one of claims 1 to 5 or its stereoisomer, tautomer or pharmaceutically acceptable salt, wherein the compound is selected from:

7. A method for preparing the compound of general formula (I) according to claim 1 or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, the method comprising: Reacting the general formula (IA) with E-(alkylene)-OMs, EC(O)X, E-(alkylene)-C(O)X or EC(O)H to obtain the general formula (I); X is selected from hydroxyl or halogen, preferably hydroxyl, Cl or Br; Among them: L1, L2, B, E, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in claim 1.

8. A compound of the general formula (IA) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: L1, B, X 1 , X 2 , X 3 , X 4 , R 1 and m are as defined in claim 1.

9. The compound according to claim 8 or its stereoisomer, tautomer or pharmaceutically acceptable salt, wherein the compound comprises:

10. A pharmaceutical composition comprising an effective dose of the compound according to any one of claims 1 to 6 or its stereoisomer, tautomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

11. Use of the compound according to any one of claims 1 to 6 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 11 in the preparation of a medicament for a RET or mutant RET inhibitor.

12. Use of the compound according to any one of claims 1 to 6 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 11 in the preparation of a medicament for treating a disease mediated by RET abnormality, wherein the disease is preferably cancer, fibrous dysplasia and genetic disorder, wherein the cancer is preferably non-small cell lung cancer, thyroid cancer, solid tumor, colon tumor or pancreatic cancer, more preferably non-small cell lung cancer, thyroid cancer, solid tumor.

13. Use of the compound according to any one of claims 1 to 6, or its stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 10, in the preparation of a medicament for treating a subject who produces antibodies to cancer.